peripheral T-cell lymphoma

It is also known as "lymphoepithelioid variant of peripheral T-cell lymphoma".

Peripheral T-cell lymphoma, not otherwise characterized.

It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma.

Peripheral T-cell lymphoma, unspecified.

Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the thymus.

Subcutaneous panniculitis-like T-cell lymphoma, is a subtype of Peripheral T-cell lymphoma.

Dr. Lennert is also recognized for first describing a variant of peripheral T-cell lymphoma in 1952, which he termed "lymphoepithelioid lymphoma."

Peripheral T-cell lymphoma (PTCL), excluding ALCL, is very rare in children.

Most investigators report worse response and survival rates for patients with peripheral T-cell lymphomas than for patients with comparably staged B-cell aggressive lymphomas.

Rodriguez J, Munsell M, Yazji S, et al.: Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

The WHO classification system classifies ALCL as a peripheral T-cell lymphoma (PTCL).

TopoTarget expects to launch an initial regulatory study using Belinostat as monotherapy to treat peripheral T-cell lymphoma (PTCL) by the beginning of 2009.

Windsor R, Stiller C, Webb D: Peripheral T-cell lymphoma in childhood: population-based experience in the United Kingdom over 20 years.

The US FDA announced the approval of pralatrexate in 2009 for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).

Reimer P, Rüdiger T, Geissinger E, et al.: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.

The most dramatic results were found in the treatment of cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs).

Talpur R, Apisarnthanarax N, Ward S, et al.: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Hutchison RE, Laver JH, Chang M, et al.: Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: a Children's Oncology Group study.

Enblad G, Hagberg H, Erlanson M, et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

It is the first drug approved as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma, or PTCL - a biologically diverse group of aggressive blood cancers that have a poor prognosis.

Rüdiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

López-Guillermo A, Cid J, Salar A, et al.: Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.

Patients with peripheral T-cell lymphoma have diffuse large cell or diffuse mixed lymphoma that expresses a cell surface phenotype of a postthymic (or peripheral) T-cell expressing CD4 or CD8 but not both together.

Romidepsin (INN, trade name Istodax), codenamed FK228 and FR901228, is an anticancer agent undergoing clinical trials as a treatment for cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma, and a variety of other cancers.